PRECLINICAL TESTING OF THE EFFICACY AND SAFETY OF CRISPR/CAS9 GENE EDITED CAR-T CELL THERAPY FOR DIFFUSE MIDLINE GLIOMA (DMG)

被引：0

作者：

Balakrishnan, Ilango ^{[1
]}

Leach, Lillie ^{[1
]}

Pierce, Angela ^{[1
]}

Lakshmanachetty, Senthilnath ^{[1
]}

Madhavan, Krishna ^{[1
]}

Fosmire, Susan ^{[1
]}

Chatwin, Hannah ^{[1
]}

Green, Adam ^{[1
]}

Fry, Terry ^{[1
]}

Vibhakar, Rajeev ^{[1
]}

Kohler, Eric. M. ^{[1
]}

Venkataraman, Sujatha ^{[1
]}

机构：

[1] Univ Colorado, Aurora, CO USA

来源：

NEURO-ONCOLOGY | 2023年 / 25卷

关键词：

D O I：

10.1093/neuonc/noad073.079

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

DIPG-32

引用

页数：1

共 50 条

[21] Enhanced CRISPR-Cas9 edited CAR-T cells through simultaneous inactivation of multiple T cell exhaustion pathways
Sergeeva, Oksana
Fearnley, Amber
Chin, Shu Shien
An, Xingyue
Pels, Nana Adjoa
Metzler, Kristen
Joinville, Kyla
Calderon, Lizet Aquino
Abulizi, Abudukadier
Karp, Hayden
Rodriguez, Julio
Matis, Louis
Fine, Jay
Myers, Jeremy
CANCER RESEARCH, 2023, 83 (07)
[22] Multiplexing of Up to 10 Gene Edits Using Crispr/Cas9 to Generate Car-T Cells with Improved Function
McEwan, Brigid
Padalia, Zinkal
Dunn, Andrew
Karagiannis, Konstantinos
Kuppuraju, Meghna
Spencer, Sarah
Dar, Henia
Minh Thu Pham
Sagert, Jason
Terrett, Jonathan
Kalaitzidis, Demetrios
MOLECULAR THERAPY, 2020, 28 (04) : 496 - 496
[23] CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells
Liu, Xiaojuan
Zhang, Yongping
Cheng, Chen
Cheng, Albert W.
Zhang, Xingying
Li, Na
Xia, Changqing
Wei, Xiaofei
Liu, Xiang
Wang, Haoyi
CELL RESEARCH, 2017, 27 (01) : 154 - 157
[24] CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells
Xiaojuan Liu
Yongping Zhang
Chen Cheng
Albert W Cheng
Xingying Zhang
Na Li
Changqing Xia
Xiaofei Wei
Xiang Liu
Haoyi Wang
Cell Research, 2017, 27 : 154 - 157
[25] CRISPR/CAS9 GENE-EDITED, ALLOGENEIC ANTI-CD83 CAR-T CELLS DEMONSTRATE POTENT ACTIVITY IN GVHD AND AML TUMOR MODELS
Oumzil, Ismael
Guerrero, Valerie
Keerthipati, Pooja Smruthi
Colangelo, Jaqlyn
Lawler, Brendan
Singson, Victoria
Khedkar, Aditya
Singh, Shweta
Terrett, Jonathan
Hostetter, Daniel
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A386 - A386
[26] Therapeutic potential of CRISPR/Cas9 gene editing in engineered T-cell therapy
Gao, Qianqian
Dong, Xuan
Xu, Qumiao
Zhu, Linnan
Wang, Fei
Hou, Yong
Chao, Cheng-chi
CANCER MEDICINE, 2019, 8 (09): : 4254 - 4264
[27] CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy
Lauren Giuffrida
Kevin Sek
Melissa A. Henderson
Junyun Lai
Amanda X. Y. Chen
Deborah Meyran
Kirsten L. Todd
Emma V. Petley
Sherly Mardiana
Christina Mølck
Gregory D. Stewart
Benjamin J. Solomon
Ian A. Parish
Paul J. Neeson
Simon J. Harrison
Lev M. Kats
Imran G. House
Phillip K. Darcy
Paul A. Beavis
Nature Communications, 12
[28] CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy
Giuffrida, Lauren
Sek, Kevin
Henderson, Melissa A.
Lai, Junyun
Chen, Amanda X. Y.
Meyran, Deborah
Todd, Kirsten L.
Petley, Emma, V
Mardiana, Sherly
Molck, Christina
Stewart, Gregory D.
Solomon, Benjamin J.
Parish, Ian A.
Neeson, Paul J.
Harrison, Simon J.
Kats, Lev M.
House, Imran G.
Darcy, Phillip K.
Beavis, Paul A.
NATURE COMMUNICATIONS, 2021, 12 (01)
[29] CRISPR/Cas9 technology: towards a new generation of improved CAR-T cells for anticancer therapies
Urena-Bailen, Guillermo
Lamsfus-Calle, Andres
Daniel-Moreno, Alberto
Raju, Janani
Schlegel, Patrick
Seitz, Christian
Atar, Daniel
Antony, Justin S.
Handgretinger, Rupert
Mezger, Markus
BRIEFINGS IN FUNCTIONAL GENOMICS, 2020, 19 (03) : 191 - 200
[30] CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed/refractory lymphoma
Guo, Yelei
Tong, Chuan
Su, Liping
Zhang, Wenying
Jia, Hejin
Liu, Yang
Yang, Qingming
Wu, Zhiqiang
Wang, Yao
Han, Weidong
BLOOD ADVANCES, 2022, 6 (08) : 2695 - 2699

← 1 2 3 4 5 →